Recent advances in subcutaneous delivery methods now enable patient self-delivery of monoclonal antibody (mAb) therapies. Subcutaneous therapies often require concentrations around 100 to 200 mg/mL.

With momentum building in recent years, several private equity industry players have been steadily acquiring their way to a complete roster of investment options representing the basic building blocks ...